Datametrex Secures Rights To New PCR Test Kit
Datametrex AI (TSXV: DM) continues to develop out its healthcare division focused on COVID-19 testing. The firm this morning revealed it has secured rights for further test kit models as it looks to increase its offerings in the category.
The latest test kit models are known as the 1POT Professional Device and the 1copy MDx Kit Professional, which are used together to reportedly provide a reading that is eight times faster than a traditional RT-PCR test.
The professional device is the part of the kit that analyzes swabs taken with the 1copy test, and is a tech-enabled device that offers smart phone compatibility. This in turn enables the device to be used in places such as hospitals, clinics and schools with healthcare professionals.
The MDx Kit is currently approved for use in the European Economic Area, as a result of it containing CE marking certification.
“The company is pleased with this new state-of-the-art testing system, opening the door to new revenue streams. A regular lab based PCR test can be substituted with the MDx kit,” commented Andrew Ryu, Chairman of Datametrex.
Datametrex AI last traded at $0.18 on the TSX Venture.
FULL DISCLOSURE: DataMetrex AI Limited is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DataMetrex AI Limited on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. We may buy or sell securities in the company at any time. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
